Advanced

Detection of hepatitis C core antigen in serum or plasma as a marker of hepatitis C viraemia in the serological window-phase.

Widell, Anders LU ; Molnegren, V; Pieksma, F; Calmann, M; Peterson, J and Lee, S R (2002) In Transfusion Medicine 12(2). p.107-113
Abstract
A new immunoassay for the detection of hepatitis C core antigen (HCVcoreAg) in peripheral blood during serological window-phase was evaluated among healthy blood donors, commercially available hepatitis C virus (HCV) seroconversion panels and in-house specimens from individuals undergoing seroconversion. Among 1964 low-risk blood donor samples, seven samples were initially reactive but only one was repeat reactive. Reactivity of this specimen was not confirmable by neutralization with specific anti-HCV core antibody, and the sample was negative for HCV RNA by polymerase chain reaction (PCR). The specificity of the HCVcoreAg enzyme-linked immunosorbent assay (ELISA) was 99.95%. In seven commercially available HCV seroconversion panels,... (More)
A new immunoassay for the detection of hepatitis C core antigen (HCVcoreAg) in peripheral blood during serological window-phase was evaluated among healthy blood donors, commercially available hepatitis C virus (HCV) seroconversion panels and in-house specimens from individuals undergoing seroconversion. Among 1964 low-risk blood donor samples, seven samples were initially reactive but only one was repeat reactive. Reactivity of this specimen was not confirmable by neutralization with specific anti-HCV core antibody, and the sample was negative for HCV RNA by polymerase chain reaction (PCR). The specificity of the HCVcoreAg enzyme-linked immunosorbent assay (ELISA) was 99.95%. In seven commercially available HCV seroconversion panels, HCVcoreAg appeared 23-46 days earlier than anti-HCV antibody by third generation assay. Additional testing with specimens from patients undergoing anti-HCV seroconversion indicated that HCVcoreAg becomes undetectable by the present test format soon after the onset of antibody. This test may be considered as an alternative to nucleic amplification techniques (NAT) for blood donor HCV screening. Additional development of technology for detecting HCVcoreAg may be useful for patient diagnosis and therapy monitoring. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Transfusion Medicine
volume
12
issue
2
pages
107 - 113
publisher
Wiley-Blackwell
external identifiers
  • pmid:11982963
  • wos:000175234400002
  • scopus:0036231713
ISSN
0958-7578
DOI
10.1046/j.1365-3148.2002.00359.x
language
English
LU publication?
yes
id
6ac5396b-d7a2-4f9b-b166-9ee7a2e2e690 (old id 107932)
alternative location
http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11982963&dopt=Abstract
date added to LUP
2007-07-27 13:23:24
date last changed
2017-07-02 04:17:32
@article{6ac5396b-d7a2-4f9b-b166-9ee7a2e2e690,
  abstract     = {A new immunoassay for the detection of hepatitis C core antigen (HCVcoreAg) in peripheral blood during serological window-phase was evaluated among healthy blood donors, commercially available hepatitis C virus (HCV) seroconversion panels and in-house specimens from individuals undergoing seroconversion. Among 1964 low-risk blood donor samples, seven samples were initially reactive but only one was repeat reactive. Reactivity of this specimen was not confirmable by neutralization with specific anti-HCV core antibody, and the sample was negative for HCV RNA by polymerase chain reaction (PCR). The specificity of the HCVcoreAg enzyme-linked immunosorbent assay (ELISA) was 99.95%. In seven commercially available HCV seroconversion panels, HCVcoreAg appeared 23-46 days earlier than anti-HCV antibody by third generation assay. Additional testing with specimens from patients undergoing anti-HCV seroconversion indicated that HCVcoreAg becomes undetectable by the present test format soon after the onset of antibody. This test may be considered as an alternative to nucleic amplification techniques (NAT) for blood donor HCV screening. Additional development of technology for detecting HCVcoreAg may be useful for patient diagnosis and therapy monitoring.},
  author       = {Widell, Anders and Molnegren, V and Pieksma, F and Calmann, M and Peterson, J and Lee, S R},
  issn         = {0958-7578},
  language     = {eng},
  number       = {2},
  pages        = {107--113},
  publisher    = {Wiley-Blackwell},
  series       = {Transfusion Medicine},
  title        = {Detection of hepatitis C core antigen in serum or plasma as a marker of hepatitis C viraemia in the serological window-phase.},
  url          = {http://dx.doi.org/10.1046/j.1365-3148.2002.00359.x},
  volume       = {12},
  year         = {2002},
}